Michael O'CAllaghan

Michael O'CAllaghan

Auto-generated profile, based on publicly available information

Michael O'CAllaghan

Flinders Medical Centre, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2015 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
GMG McMichael
G McMichael
MBM N Bainbridge
M N Bainbridge
EHE Haan
E Haan
MCM Corbett
M Corbett
AGA Gardner
A Gardner
AMA H MacLennan
A H MacLennan

1 September 2011 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
MOMichael E. Bsc (Hons) O'Callaghan
Michael E. Bsc (Hons) O'Callaghan
AMAlastair H. MacLennan
Alastair H. MacLennan
CGCatherine S. Gibson
Catherine S. Gibson
GMGai L. McMichael
Gai L. McMichael
EHEric A. Mbbs Haan
Eric A. Mbbs Haan
GDGustaaf A. Dekker
Gustaaf A. Dekker
OBJECTIVE: To estimate epidemiologic risk factors for cerebral palsy. METHODS: Data were collected by linkage to state-based perinatal repositories and cerebral palsy registers and using a maternal questionnaire. The cohort included 587 individuals with cerebral palsy and 1,154 non–cerebral palsy controls. RESULTS: The following factors were associated with cerebral palsy: recorded maternal infection during pregnancy (41.4% patients compared with 31.3% controls; odds ratio [OR] 1.55, 95% confidence interval 1.26–1.91), small for gestational age ([birth weight less than third customized centile] 43.9% patients compared with 6.3% controls; OR 11.75, 6.25–22.08), gestational age less than 32 weeks (29.3% patients compared with 0.7% controls; OR 59.20, 28.87–121.38), multiple birth (OR 6.62, 4.00–10.95), a relative with cerebral palsy (OR 1.61, 1.12–2.32), breech position (13.7% patients compared with 6.0% controls; OR 2.48, 1.76–3.49), bleeding at any time in pregnancy (29.3% patients compared with 16.9% controls; OR 2.04, 1.61–2.58), male sex (58.8% patients compared with 45.8% controls; OR 1.68, 1.38–2.06), multiple miscarriage (7.7% patients compared with 3.5% controls; OR 2.30, 1.38–3.82), smoking (14.0% patients compared with 10.6% controls; OR 1.37, 1.02–1.85), and illicit drug use (3.3% patients compared with 1.5% controls; OR 2.22, 1.14–4.30). Factors not associated with cerebral palsy were “disappearing twin,” diabetes, maternal body mass index, hypertension, alcohol consumption, anemia, maternal hypothyroidism, forceps or vacuum delivery, and maternal age. CONCLUSION: Preterm birth, intrauterine growth restriction, perinatal infection, and multiple birth present the largest risks for a cerebral palsy outcome. Reassuringly, upper respiratory tract and gastrointestinal infections during pregnancy were not associated with cerebral palsy. LEVEL OF EVIDENCE: II

17 December 2019 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
NKNed Kinnear
Ned Kinnear
DBDylan Barnett
Dylan Barnett
MOMichael O'Callaghan
Michael O'Callaghan
KHKym Horsell
Kym Horsell
JGJohan Gani
Johan Gani
DHDerek Hennessey
Derek Hennessey

1 June 2010 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
GKGabriel Kremmidiotis
Gabriel Kremmidiotis
ALAnnabell F. Leske
Annabell F. Leske
TLTina C. Lavranos
Tina C. Lavranos
DBDonna Beaumont
Donna Beaumont
JGJelena Gasic
Jelena Gasic
BFBernard Flynn
Bernard Flynn
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow therapeutic margin, with cardiovascular toxicity posing a dose-limiting obstacle. Discovery of new VDAs, which display a wider therapeutic margin, may allow attainment of improved clinical outcomes. To identify such compounds, we used an in vitro selectivity screening approach that exploits the fact that tumor endothelial cells are in a constant state of activation and angiogenesis and do not undergo senescence. Our effort yielded the compound BNC105. This compound acts as a tubulin polymerization inhibitor and displays 80-fold higher potency against endothelial cells that are actively proliferating or are engaged in the formation of in vitro capillaries compared with nonproliferating endothelial cells or endothelium found in stable capillaries. This selectivity was not observed with CA4, a VDA currently under evaluation in phase III clinical trials. BNC105 is more potent and offers a wider therapeutic window. CA4 produces 90% vascular disruption at its no observed adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL. Tissue distribution analysis of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 hours after administration, it is still present at high concentrations within the solid tumor mass. Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals. Mol Cancer Ther; 9(6); 1562–73. ©2010 AACR.

24 February 2009 in Human Genetics
Verified
Journal Article
Closed access
PDF file
TGThe South Australian Cerebral Palsy Research Group
The South Australian Cerebral Palsy Research Group
MOM. E. O’cAllaghan
M. E. O’cAllaghan
AMA. H. MacLennan
A. H. MacLennan
EHE. A. Haan
E. A. Haan
GDG. Dekker
G. Dekker

26 September 2022 in BJU International
Verified
Journal Article
Open access
FHFrances Harley
Frances Harley
GWGavin Wei
Gavin Wei
MOMichael O'CAllaghan
Michael O'CAllaghan
LWLih‐Ming Wong
Lih‐Ming Wong
DHDerek Hennessey
Derek Hennessey
NKNed Kinnear
Ned Kinnear
Objectives: To systematically review the current demographics, treatment and mortality rate associated with xanthogranulomatous pyelonephritis (XGP) and to test the hypothesis that the weighted pooled peri‐operative mortality rate will be <10%. Methods: Searches were performed of the Cochrane, Embase and Medline databases and the grey literature for studies published during the period 1 January 2000 to 30 August 2021. Eligible studies reported cohorts of ≥10 predominantly adult patients with XGP and described either average patient age or mortality rate. Results: In total, 40 eligible studies were identified, representing 1139 patients with XGP. There were 18 deaths, with a weighted pooled peri‐operative mortality rate of 1436 per 100 000 patients. The mean age was 49 years, 70% of patients were female and 28% had diabetes mellitus. The left kidney was more commonly affected (60%). Four patients had bilateral XGP, and all of whom survived. Renal or ureteric stones were present in 69% of patients, including 48% with staghorn calculi. Urine culture was positive in 59% of cases. Fistulae were present in 8%. Correct preoperative diagnosis occurred in only 45% of patients. Standard treatment continues to comprise a short cause of antibiotics and open radical (total) nephrectomy. Preoperative decompression occurred in 56% of patients. When considered at all, laparoscopic nephrectomy was performed in 34% of patients. Partial nephrectomy was conducted in 2% of patients. Conclusions: Xanthogranulomatous pyelonephritis has a lower mortality rate than historically reported. A typical patient is a woman in her fifth or sixth decade of life with urolithiasis. While open radical nephrectomy remains the most common treatment method, laparoscopic, and to a lesser degree partial nephrectomy, are feasible in well selected patients.